Last reviewed · How we verify
Antibiotics
At a glance
| Generic name | Antibiotics |
|---|---|
| Also known as | Piperacillin/tazobactam, Ceftazidime, Cefepime, Daptomycin, Ceftolozane/tazobactam |
| Sponsor | St. Joseph's Healthcare Hamilton |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Learning Process of Fourth Year Medical Students During a Doctor-patient Relationship Training
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot (PHASE4)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotics CI brief — competitive landscape report
- Antibiotics updates RSS · CI watch RSS
- St. Joseph's Healthcare Hamilton portfolio CI